Monday, February 16, 2026 2/16/2026

Development of the first thermolytic to suppress shivering and seizure

Award Number: R41HL135964
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2017
PERIOD OF PERFORMANCE END DATE: 08/31/2020

Group Awards By:

View Award Description

Development of the first thermolytic to suppress shivering and seizure - Summary The temperature management market is expected to reach $2.6 billion by 2020, yet no pharmaceutical has yet been developed specifically for this market. A1 adenosine (A1AR) agonists are well known to attenuate seizure and protect the brain from injury, but development of these drugs has been limited by side-effects including hypothermia, bradycardia and hypotension. Inspired by our discoveries that 6N cyclohexyl adenosine (CHA) lowers body temperature and induces hibernation and that cardiovascular side-effects of CHA can be reversed with a peripherally acting adenosine receptor antagonist 8-(p-Sulfophenyl)theophylline (8-SPT) without affecting body temperature, the present proposal aims to meet three milestones that will define the market to target for commercialization. Aim 1 is to meet our first milestone which is to demonstrate that CHA/ 8-SPT attenuates shivering better than state-of-the-art meperidine/buspirone in rats cooled to 33°C. Aim 2 is to meet our second milestone which is to demonstrate CHA/ 8-SPTattenuates seizure better than meperidine/buspirone and Aim 3 is to meet our third milestone to demonstrate neuroprotective efficacy of CHA/8-SPT at target temperatures of 33°C and 36°C while showing that CHA/8-SPT controls shivering and seizure at both target temperatures. When completed we will have necessary preliminary data to define the thermolytic, antiseizure and neuroprotective efficacy and side effects of CHA/8-SPT relative to the state-of-the-art antishivering medication. These outcomes will be accomplished through standard methods currently used in the PI's laboratory. The results will significantly contribute to proving the scientific and technical feasibility of developing CHA combined with 8-SPT as a novel thermolytic and antiseizure medication that will make targeted temperature management accessible to underserved populations and meet market demand to treat post-operative shivering. The proposed work is necessary to justify additional support in Phase II.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2017	BE COOL PHARMACEUTICS LLC	1764 TANANA LOOP, STE 424	FAIRBANKS	AK	99775	FAIRBANKS NORTH STAR	USA	Cardiovascular Diseases Research	000	1	7/22/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2017	BE COOL PHARMACEUTICS LLC	1764 TANANA LOOP, STE 424	FAIRBANKS	AK	99775	FAIRBANKS NORTH STAR	USA	Cardiovascular Diseases Research	000	1	9/10/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $158,435 )
2019	2019	BE COOL PHARMACEUTICS LLC	1764 TANANA LOOP, STE 424	FAIRBANKS	AK	99775	FAIRBANKS NORTH STAR	USA	Cardiovascular Diseases Research	005	1	8/1/2019	SUPPLEMENT FOR EXPANSION	$0
2019	2019	BE COOL PHARMACEUTICS LLC	1764 TANANA LOOP, STE 424	FAIRBANKS	AK	99775	FAIRBANKS NORTH STAR	USA	Cardiovascular Diseases Research	004	1	8/1/2019	SUPPLEMENT FOR EXPANSION	$0
2019	2019	BE COOL PHARMACEUTICS LLC	1764 TANANA LOOP, STE 424	FAIRBANKS	AK	99775	FAIRBANKS NORTH STAR	USA	Cardiovascular Diseases Research	002	1	4/23/2019	SUPPLEMENT FOR EXPANSION	$0
2019	2019	BE COOL PHARMACEUTICS LLC	970 WATER THRUSH DR	FAIRBANKS	AK	99712	FAIRBANKS NORTH STAR	USA	Cardiovascular Diseases Research	000	1	12/18/2018	SUPPLEMENT FOR EXPANSION	$103,435
2019	2019	BE COOL PHARMACEUTICS LLC	1764 TANANA LOOP, STE 424	FAIRBANKS	AK	99775	FAIRBANKS NORTH STAR	USA	Cardiovascular Diseases Research	001	1	3/15/2019	SUPPLEMENT FOR EXPANSION	$55,000
2019	2017	BE COOL PHARMACEUTICS LLC	1764 TANANA LOOP, STE 424	FAIRBANKS	AK	99775	FAIRBANKS NORTH STAR	USA	Cardiovascular Diseases Research	003	1	8/1/2019	NEW	$0
														Subtotal = $158,435

Issue Date FY: 2017 ( Subtotal = $298,871 )
2017	2017	BE COOL PHARMACEUTICS LLC	970 WATER THRUSH DR	FAIRBANKS	AK	99712	FAIRBANKS NORTH STAR	USA	Cardiovascular Diseases Research	000	1	8/29/2017	NEW	$298,871
														Subtotal = $298,871

Grand Total All Awards = $457,306

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of the first thermolytic to suppress shivering and seizure

Award Number: R41HL135964

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2017

PERIOD OF PERFORMANCE END DATE: 08/31/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer